Structure Therapeutics Reports Positive GSBR-1290 Phase 1b Trial Results; Stock Climbs In Premarket

Structure Therapeutics Inc. (GPCR), a clinical-stage biopharmaceutical company focused on chronic metabolic and cardiopulmonary conditions, announced Friday positive results from Phase 1b clinical study of oral GLP-1 receptor agonist GSBR-1290 in healthy overweight or obese individuals. The company continues to plan to initiate two Phase 2b studies of GSBR-1290 in type 2 diabetes and obesity in 2024.

In pre-market activity on Nasdaq, Structure Therapeutics shares were gaining around 75 percent to trade at $65.70.

In the 28-day Phase 1b multiple ascending dose or MAD study, GSBR-1290 demonstrated significant weight loss supporting once-daily or QD dosing and an encouraging safety and tolerability profile. GSBR-1290 demonstrated reductions in mean body weight ranging up to 4.9 kg compared to baseline, and up to 4.9% placebo-adjusted.

Raymond Stevens, Founder and CEO of Structure, said, “GSBR-1290 demonstrated an encouraging safety and tolerability profile with no adverse event-related discontinuations and we are encouraged by the weight loss observed following four weeks of treatment. We look forward to sharing results of GSBR-1290 over a longer 12-week period in the Phase 2a study, and we continue to move forward with all activities in order to begin Phase 2b clinical trials in both type 2 diabetes and obesity as planned in 2024.”

Structure said it remains on track to report topline data from the type 2 diabetes cohort of the Phase 2a study in the latter half of the fourth quarter of 2023 as planned, along with results from the Japanese ethno-bridging study of GSBR-1290.

Regarding the Phase 2b studies of GSBR-1290, the company said the type 2 diabetes study is expected to include around 500 individuals across the United States, Europe and Japan. The obesity study would include around 275 individuals across the United States and Europe.

For More Such Health News, visit rttnews.com

Source: Read Full Article